In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement with Novartis AG, potentially valued at up to $2.5 billion. This strategic alliance aims to leverage Schrödinger’s advanced computational platform to accelerate drug discovery and development across various therapeutic areas. Under the terms of the agreement, Schrödinger […]
Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development has positioned Bristol Myers Squibb as a stronger player in the highly competitive and lucrative schizophrenia treatment market, as AbbVie’s setback gives Bristol Myers Squibb an unexpected advantage. AbbVie recently […]
Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data from their Phase 1/2a study on a melanoma treatment yielded mixed results. Analysts and investors reacted to the company’s announcement that lower doses of the radiopharmaceutical [212Pb]VMT01 were more effective compared to higher doses, while an unexpected […]
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly after announcing a $150 million public offering. The announcement came as a surprise to investors, with the stock experiencing a sharp drop of approximately 10%, closing at $9.95 from its previous levels above $11. This downturn has […]
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb’s Opdivo (nivolumab). The latest approval allows the immunotherapy to be used in adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy as part of a perioperative […]
Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term survival benefits of the Opdivo (nivolumab) and Yervoy (ipilimumab) combination in treating advanced melanoma. These results, revealed at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, mark the longest reported median overall survival […]